Share

Best time to buy Celgene, Vertex & more

The biotech ETF soared 67 percent in 2013, but has since been bumpy. Discussing winning and losing stocks in the industry, with Mark Schoenebaum, ISI pharma/biotech analyst.
04:10
Fri, Jun 27 201412:17 PM EDT